Tesaro Inc. (NASDAQ:TSRO) shares dropped 2.1% on Tuesday . The stock traded as low as $85.74 and last traded at $86.31, with a volume of 383,629 shares traded. The stock had previously closed at $88.20.

TSRO has been the subject of several recent research reports. Mizuho reaffirmed an “outperform” rating and set a $67.00 price objective on shares of Tesaro in a research report on Thursday, June 30th. FBR & Co reaffirmed a “buy” rating on shares of Tesaro in a research report on Thursday, June 30th. Wells Fargo & Co. reaffirmed an “outperform” rating on shares of Tesaro in a research report on Thursday, June 30th. Wedbush reaffirmed an “outperform” rating and set a $72.00 price objective on shares of Tesaro in a research report on Wednesday, April 6th. Finally, Zacks Investment Research raised Tesaro from a “sell” rating to a “hold” rating in a research report on Tuesday, July 5th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Tesaro has a consensus rating of “Buy” and a consensus target price of $73.91.

The firm’s market capitalization is $3.95 billion. The stock’s 50 day moving average price is $53.34 and its 200-day moving average price is $44.70.

Tesaro (NASDAQ:TSRO) last issued its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($2.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.69) by $0.53. The company earned $0.31 million during the quarter, compared to analyst estimates of $2.48 million. During the same period last year, the firm earned ($1.30) earnings per share. Equities analysts anticipate that Tesaro Inc. will post ($7.11) EPS for the current year.

In other Tesaro news, VP Jeffrey H. Hanke sold 12,500 shares of the business’s stock in a transaction that occurred on Thursday, June 30th. The stock was sold at an average price of $74.35, for a total transaction of $929,375.00. Following the completion of the sale, the vice president now directly owns 12,500 shares of the company’s stock, valued at approximately $929,375. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Edward C. English sold 7,000 shares of the business’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $40.75, for a total value of $285,250.00. Following the sale, the vice president now directly owns 3,500 shares of the company’s stock, valued at $142,625. The disclosure for this sale can be found here.

A number of hedge funds recently modified their holdings of the company. Jennison Associates LLC raised its stake in shares of Tesaro by 157.5% in the fourth quarter. Jennison Associates LLC now owns 938,461 shares of the biopharmaceutical company’s stock worth $49,100,000 after buying an additional 574,041 shares in the last quarter. Whittier Trust Co. raised its stake in shares of Tesaro by 1.1% in the fourth quarter. Whittier Trust Co. now owns 20,945 shares of the biopharmaceutical company’s stock worth $1,096,000 after buying an additional 220 shares in the last quarter. BB Biotech AG raised its stake in shares of Tesaro by 6.5% in the fourth quarter. BB Biotech AG now owns 1,229,582 shares of the biopharmaceutical company’s stock worth $64,332,000 after buying an additional 75,000 shares in the last quarter. Bank of Montreal Can raised its stake in shares of Tesaro by 9,925.5% in the fourth quarter. Bank of Montreal Can now owns 24,362 shares of the biopharmaceutical company’s stock worth $1,275,000 after buying an additional 24,119 shares in the last quarter. Finally, Mutual of America Capital Management LLC raised its stake in shares of Tesaro by 95.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 39,520 shares of the biopharmaceutical company’s stock worth $2,068,000 after buying an additional 19,320 shares in the last quarter.

TESARO, Inc (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.